Johnson & Johnson to Address Racial and Social Injustice Through Platform that Aims to Eliminate Health Inequities for People of Color
NEW BRUNSWICK, N.J., November 17, 2020 – Johnson & Johnson announced today $100 million in commitments and collaborations over the next five years to invest in and promote health equity solutions for Black people and other communities of color in the United States. Society has been significantly impacted by systemic racism, the COVID-19 pandemic, and the economic decline throughout this year, which have all spotlighted healthcare inequities. “There is an urgent need to take on the inequities rooted in systemic racism that threaten health in communities of color across the United States,” said Alex Gor...
Source: Johnson and Johnson - November 17, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Initiates Second Global Phase 3 Clinical Trial of its Janssen COVID-19 Vaccine Candidate
November 15, 2020 -- The Phase 3 ENSEMBLE study of the single-dose regimen of JNJ-78436735, the investigational vaccine candidate for the prevention of COVID-19 being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, continues to enroll and vaccinate study participants. ENSEMBLE is proceeding to enroll up to 60,000 participants worldwide.In addition to the single-dose regimen ENSEMBLE study, Janssen has now initiated the two-dose regimen ENSEMBLE 2 trial. ENSEMBLE 2 is a complementary, planned, pivotal, large-scale, multi-country Phase 3 trial that will study the safety and efficacy of a two-dose ...
Source: Johnson and Johnson - November 16, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson and U.S. Department of Health & Human Services Expand Agreement to Support Next Phase of COVID-19 Vaccine Candidate Research and Development
NEW BRUNSWICK, N.J., November 14, 2020 – Johnson & Johnson (the Company) announced the expansion to the partnership between its Janssen Pharmaceutical Companies (Janssen) and the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services for the ongoing development of Janssen’s investigational COVID-19 vaccine candidate.Under the amendment, Janssen will commit approximately $604 million and BARDA will commit approximately $454 million to support the ongoing Pha...
Source: Johnson and Johnson - November 14, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need f...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson to Host Virtual Medical Devices Update
NEW BRUNSWICK, NJ – November 6, 2020 – Johnson & Johnson (NYSE: JNJ) will hold a virtual Medical Devices Update for the investment community on Thursday, November 19, 2020, in which leadership will focus on the Company’s differentiated and competitive platforms across digital surgery and provide franchise and innovation highlights across the Johnson & Johnson Medical Devices Companies.“We look forward to providing an update on the strength of our Medical Devices business and how we are positioning ourselves for long-term success through meaningful innovation that will continue to make a diff...
Source: Johnson and Johnson - November 6, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revasculariz...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
Discussions with other regulators around the world to resume the clinical trial program are progressing. After a thorough evaluation of a serious medical event experienced by one study participant, no clear cause has been identified. There are many possible factors that could have caused the event. Based on the information gathered to date and the input of independent experts, the Company has found no evidence that the vaccine candidate caused the event.At Johnson & Johnson, there is no greater priority than the health and safety of the people we serve every day around the world. Our primary goal is to ensure the safet...
Source: Johnson and Johnson - October 23, 2020 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference
New Brunswick, NJ (October 15, 2020) -- Johnson & Johnson (NYSE: JNJ) will participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on Wednesday, November 11th. Joaquin Duato, Vice Chairman of the Executive Committee and Thibaut Mongon, Executive Vice President, Worldwide Chairman Consumer Health will represent the Company in a session scheduled at 11:45 a.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.A webcast replay will be available approximately 48-hours after the live webcast. (Sou...
Source: Johnson and Johnson - October 15, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 ...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Statement on Opioid Resolution
October 13, 2020 – Johnson & Johnson and its U.S.-based Janssen Pharmaceutical Companies disclosed that the Company will contribute up to an additional $1 billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments. This amount represents an increase to the $4 billion agreement in principle announced by a committee of State Attorneys General on October 21, 2019, for a total of $5 billion. Additional terms and conditions are still being finalized. This additional amount results from continued negotiations and is intended to ma...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Temporarily Pauses All Dosing in Our Janssen COVID-19 Vaccine Candidate Clinical Trials
At Johnson & Johnson, there is no greater priority than the safety and well being of the people we serve every day around the world. We are committed to providing transparent updates throughout the clinical development process of our vaccine candidate, in compliance with regulatory standards and our own high ethical and scientific principles.We have temporarily paused further dosing in all our COVID-19 vaccine candidate clinical trials, including the Phase 3 ENSEMBLE trial, due to an unexplained illness in a study participant. Following our guidelines, the participant’s illness is being reviewed and evaluated by ...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Source Type: news

Champions of Science: Breaking the Stigma of Mental Illness
NEW BRUNSWICK, NJ – October 8, 2020 – As the COVID-19 pandemic continues to increase stress, fear, and uncertainty worldwide, there has never been a more critical time to champion mental healthcare. Join us virtually for the Champions of Science: Breaking the Stigma of Mental Illness webcast, open to the public, on Thursday, October 15, 2020, at 12:00 p.m. ET via Johnson & Johnson’s page on LinkedIn. During the event, we will speak to scientists, advocates, and global experts who are working tirelessly to ensure stigma does not stand in the way of people living with mental illness seeking the care and...
Source: Johnson and Johnson - October 8, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Announces European Commission Approval of Agreement to Supply 200 Million Doses of Janssen ’s COVID-19 Vaccine Candidate
New Brunswick, N.J., October 8, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Purchase Agreement in which the Janssen Pharmaceutical Companies will supply 200 million doses of its COVID-19 vaccine candidate to EU Member States following approval or authorization from regulators. The EU Member States also have the option to secure up to 200 million additional doses.“The COVID-19 pandemic continues to threaten communities worldwide and we have a responsibility to ensure access ...
Source: Johnson and Johnson - October 8, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Completes Acquisition of Momenta Pharmaceuticals, Inc.
NEW BRUNSWICK, N.J., October 1, 2020 -- Johnson & Johnson (NYSE: JNJ) today announced it has successfully completed its acquisition of Momenta Pharmaceuticals, Inc. (“Momenta”), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 billion.“We’re delighted to welcome Momenta’s talented team to the Janssen Pharmaceutical Companies of Johnson & Johnson and to begin our work together to further advance patient care in autoantibody-driven diseases,” said Jennifer Taubert, Executive Vice President, Worldwi...
Source: Johnson and Johnson - October 1, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glo...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news

Janssen Submits New Drug Application (NDA) to U.S. FDA for UPTRAVI ® (selexipag) Injection for Intravenous Use to Treat Pulmonary Arterial Hypertension (PAH)
SOUTH SAN FRANCISCO, CA – September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for UPTRAVI® (selexipag) as an injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adults with WHO functional class (FC) II–III, who are currently prescribed oral UPTRAVI but are temporarily unable to take oral therapy. In patients with PAH, interruptions in treatment should be avoided due to the progressive nature of the disease...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

(This statement was updated on October 4, 2020 to include additional information) Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate
Interim analysis from the ongoing Phase 1/2a clinical trial of the Janssen COVID-19 vaccine candidate (JNJ-78436735) was posted today on the pre-print server medRxiv.The data demonstrate that a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants aged 18 years and older and was generally well-tolerated. Immune responses were similar across the age groups studied, including older adults. The ongoing Phase 1/2a clinical trial is designed to study the safety and immunogenicity of two dose levels of the Janssen COVID-19 vaccine, and as single and two-dose schedules. The interim...
Source: Johnson and Johnson - September 25, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate
Interim analysis from the ongoing Phase 1/2a clinical trial of the Janssen COVID-19 vaccine candidate (JNJ-78436735) was posted today on the pre-print server medRxiv.The data demonstrate that a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants aged 18 years and older and was generally well-tolerated. Immune responses were similar across the age groups studied, including older adults. The ongoing Phase 1/2a clinical trial is designed to study the safety and immunogenicity of two dose levels of the Janssen COVID-19 vaccine, and as single and two-dose schedules. The interim...
Source: Johnson and Johnson - September 25, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen ’s COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., September 23, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from the Company’s Phase 1/2a clinical study, which demonstrated that the safety profile and immunogenicity after a single vaccination were supportive of further development. These results have been submitted to medRxiv and are due to be published online i...
Source: Johnson and Johnson - September 23, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Business Continuity Statement (9/23)
In our role as a global health leader, Johnson & Johnson is closely monitoring the COVID-19 (coronavirus) pandemic and taking steps to help prevent the spread of the virus as well as exploring the potential for a vaccine.We have robust business continuity plans in place across our global supply chain network to prepare for unforeseen events and to meet the needs of the patients, customers and consumers who depend on our products. These steps include maintaining critical inventory at major distribution centers away from high-risk areas and working with external suppliers to support our preparedness plans.The need for in...
Source: Johnson and Johnson - September 23, 2020 Category: Pharmaceuticals Tags: Corporate Source Type: news

BAND-AID ® Brand Delivers Modern Day “CARE Packages” to Frontline Workers
expand FORT WASHINGTON, P.A., Sept. 21, 2020 /PR Newswire/ – BAND-AID® Brand of Johnson & Johnson Consumer Health today announced a strategic partnership with global humanitarian leader CARE®, the creator of the original CARE Package®, delivering aid to caregivers on the front lines of the COVID-19 pandemic, including meals, PPE and critical healthcare and delivery services[1]. To commemorate its 100th anniversary, BAND-AID® Brand is making a $100,000 donation to CARE®, and encouraging consumers to send CARE Packages to support frontline heroes and caregivers around the world for ...
Source: Johnson and Johnson - September 21, 2020 Category: Pharmaceuticals Source Type: news

Call for Award Applicants: Johnson & Johnson Seeks Female Researchers Working in Science, Technology, Engineering, Math, Manufacturing and Design
NEW BRUNSWICK, N.J. (September 14, 2020) – Johnson & Johnson today announced that it is accepting applications for its 2021 Women in STEM2D (WiSTEM2D) Scholars Award, aimed at supporting assistant or associate academic professors in the disciplines of Science, Technology, Engineering, Math, Manufacturing and Design. For three years, each recipient will receive mentorship from leaders at Johnson & Johnson and a total $150,000 ($50,000 each year). The deadline for applications is Oct. 15, 2020 at 9 a.m. HST, and guidelines and additional details are available here: https://www.jnj.com/wistem2d-university-schola...
Source: Johnson and Johnson - September 14, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
New Brunswick, NJ (September 14th, 2020) - Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 13th to review third-quarter results. Joseph J. Wolk, Executive Vice President, Chief Financial Officer and Christopher DelOrefice, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s executive team.Investors and other interested parties can access the webcast/conference call in the following ways:The webcast and presentation material are acces...
Source: Johnson and Johnson - September 14, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Medical Devices Companies Launches ‘My Health Can’t Wait’ To Encourage Patients to Prioritize Their Health and Give Them the Information They Need to Pursue Care with Confidence
Discussion Guide to help people have conversations with their healthcare professionalsSafety FAQs detailing safety measures taken by hospitals and surgery centers to help protect patients from COVID-19Telehealth 101 Resources to help patients understand the use of telehealth for routine and pre-/post-op care, as nearly three-quarters of the survey participants (73%) say they would be comfortable using telehealth services as a way of managing their healthcare1Patient Stories, and moreResource materials will also be available to healthcare professionals to strengthen communication between surgeons and patients/caregivers, as...
Source: Johnson and Johnson - September 10, 2020 Category: Pharmaceuticals Source Type: news

CERENOVUS Launches New Suite of Technologies to Advance Stroke Treatment
IRVINE, CA – September 9, 2020 – CERENOVUS, part of Johnson & Johnson Medical Devices Companies* today announced that it has launched CERENOVUS Stroke Solutions™, which includes a suite of three devices designed to aid physicians in clot removal procedures. The announcement was made during the virtual European Society of Minimally Invasive Neurological Therapy (ESMINT).Strokes are the second leading cause of death globally, and account for an estimated 140,000 deaths in the United States each year.[i],[ii] Over half of stroke survivors become chronically disabled placing an estimated $34 billion econo...
Source: Johnson and Johnson - September 9, 2020 Category: Pharmaceuticals Source Type: news

Biopharma Leaders Unite To Stand With Science
NEW YORK, September 8, 2020 — The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and Canada, Moderna, Inc. (Nasdaq: MRNA), Novavax, Inc. (Nasdaq: NVAX), Pfizer Inc. (NYSE: PFE), and Sanofi (NASDAQ: SNY), today announced a historic pledge, outlining a united commitment to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines. All nine CEOs signed the following pledge: We, the un...
Source: Johnson and Johnson - September 8, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Announces that Janssen ’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies
Janssen’s lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, prevented severe clinical disease in Syrian golden hamsters, upon challenge with SARS-CoV-2, the virus that causes COVID-19 in people. The data, published today in Nature Medicine, demonstrated that the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited an immune response as demonstrated by “neutralizing antibodies” and prevented severe clinical disease – including weight loss, pneumonia and mortality – in Syrian golden hamsters upon challenge.This publication follows Johnson &...
Source: Johnson and Johnson - September 3, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Announces Agreement in Principle with Government of Canada to Supply its COVID-19 Vaccine Candidate
MONTRÉAL, QC - August 31, 2020 - Janssen Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has agreed in principle to supply the Government of Canada with doses of its SARS-CoV-2 vaccine candidate, Ad26.COV2.S. The availability of the vaccine candidate is subject to its successful development and Health Canada regulatory approval. “We are deeply committed to providing global access to our SARS-CoV-2 vaccine candidate. As we proceed with development of our vaccine, we are simultaneously working with partners around the world, including the Government of Canada...
Source: Johnson and Johnson - August 31, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Celebrates Role of Scientists In Society with 2020 Dr. Paul Janssen Award for Biomedical Research, Part of the Champions of Science ® Initiative
NEW BRUNSWICK, NJ – August 20, 2020 – Johnson & Johnson today announced Lewis Cantley, Ph.D., of Weill Cornell Medicine and NewYork-Presbyterian as the winner of the 2020 Dr. Paul Janssen Award for Biomedical Research for his incisive research revealing the fundamental aspects of metabolism that have profound implications for the understanding, diagnosis and treatment of human diseases such as cancer and diabetes. “Like all of the past Dr. Paul Janssen Award winners, and indeed like Dr. Janssen himself, Dr. Cantley challenged the status quo, asked provocative questions, and tirelessly followed his cur...
Source: Johnson and Johnson - August 20, 2020 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in the 18th Annual Morgan Stanley Virtual Global Healthcare Conference
New Brunswick, NJ (August 20, 2020) -- Johnson & Johnson (NYSE: JNJ) will participate in the 18th Annual Morgan Stanley Virtual Global Healthcare Conference on Wednesday, September 16th. Alex Gorsky, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 10:15 a.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.A webcast replay will be available approximately two hours after the live webcast. (Source: Johnson and Johnson)
Source: Johnson and Johnson - August 20, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen ’s Leadership in Novel Treatments for Autoimmune Diseases
NEW BRUNSWICK, N.J., August 19, 2020 – Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 billion. This acquisition provides an opportunity for the Janssen Pharmaceutical Companies of Johnson & Johnson to broaden its leadership in immune-mediated diseases and drive further growth through expansion into autoantibody-driven disease. The transaction will include full global rights to nipocalim...
Source: Johnson and Johnson - August 19, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson statement on the launch of new CARE (Corona Accelerated R & D in Europe) consortium, Europe ’s largest, multi-partner scientific research initiative dedicated to discovering and developing urgently needed treatment options for COVID-19
Attributed to Marnix Van Loock, Senior Scientific Director and R&D Lead of Emerging Pathogens, Global Public Health, Janssen Pharmaceutica NV and CARE project leaderJohnson & Johnson is proud to announce that it is founding and co-leading the new CARE (Corona Accelerated R&D in Europe) consortium, Europe’s largest, multi-partner scientific research initiative dedicated to discovering and developing urgently needed treatment options for COVID-19. In this role, we are helping bring together Europe’s best and brightest scientific minds from 37 renowned academic institutions, research organizations and ...
Source: Johnson and Johnson - August 18, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson to Participate in Wells Fargo 2020 Virtual Healthcare Conference
New Brunswick, NJ (August 17, 2020) -- Johnson & Johnson (NYSE: JNJ) will participate in the Wells Fargo 2020 Virtual Healthcare Conference on Wednesday, September 9th. Mathai Mammen, Global Head, Research & Development Janssen Research Development will represent the Company in a session scheduled at 10:40 a.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.A webcast replay will be available approximately two hours after the live webcast. (Source: Johnson and Johnson)
Source: Johnson and Johnson - August 17, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson to Participate in Barclays Global Consumer Staples Virtual Conference
New Brunswick, NJ (August 14, 2020) -- Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Consumer Staples Virtual Conference on Tuesday, September 8th. Thibaut Mongon, Executive Vice President Worldwide Chairman Consumer Health will represent the Company in a session scheduled at 1:20 p.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.A webcast replay will be available approximately two hours after the live webcast. (Source: Johnson and Johnson)
Source: Johnson and Johnson - August 14, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine
New Brunswick, N.J., August 05, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen’s SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the United States following approval or Emergency Use Authorization by the U.S. Food and Drug Administration (FDA). The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of th...
Source: Johnson and Johnson - August 5, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Announces U.S. FDA Approval of SPRAVATO ® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior
TITUSVILLE, N.J. – (August 3, 2020) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation orbehavior.1 SPRAVATO® is the first and only approved medicine that has been shown to reduce depressive symptoms within 24 hours,1 providing a new option for significant symptom relief until a longer-te...
Source: Johnson and Johnson - August 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

U.S. FDA Grants Ethicon Breakthrough Device Designation for Monarch-enabled NeuWave Microwave Ablation Technology
New Brunswick, N.J., July 30, 2020 – Ethicon*, part of the Johnson & Johnson Medical Devices Company**, announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for transbronchial microwave ablation technology using robotic-assisted bronchoscopy, which is currently under development. The Breakthrough Devices Program is a voluntary program for certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The goal of the Breakthrough Devices Program is to provide patients and health car...
Source: Johnson and Johnson - July 31, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies
NEW BRUNSWICK, N.J., July 30, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The data, published in Nature, show the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by “neutralizing antibodies,” successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates (NHPs) in the pre-clinical s...
Source: Johnson and Johnson - July 30, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson to Participate in Citi ‘Of Hearts and Minds’ Conference Call Series
New Brunswick, NJ (July 17, 2020) -- Johnson & Johnson (NYSE: JNJ) will participate in Citi ‘Of Hearts and Minds’ Conference Call Series on Monday, July 27th. Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices will represent the Company in a session scheduled at 3:00 p.m. (Eastern Time). This conference call will be available to investors and other interested parties by dialing 1-856-344-9142, confirmation code: 9339323 or visit the Johnson & Johnson website at www.investor.jnj.com. (Source: Johnson and Johnson)
Source: Johnson and Johnson - July 17, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Interim Six-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosa
Click to Access Audio Press ReleaseRARITAN, NJ, July 17, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today six-month data from the ongoing Phase 1/2 trial (NCT03252847) of its investigational gene therapy for the treatment of inherited retinal disease X-linked retinitis pigmentosa (XLRP). The interim data showed that low and intermediate doses of the investigational adeno-associated virus retinitis pigmentosa GTPase regulator (AAV-RPGR) were generally well-tolerated and indicated significant improvement in vision. Initial data on the novel AAV-RPGR asset, jointly developed with Meir...
Source: Johnson and Johnson - July 17, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic...
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

TREMFYA ® (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
HORSHAM, PA, July 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.[1],[2] TREMFYA is the first treatment approved for active PsA that selectively inhibits interleukin (IL)-23, a naturally occurring cytokine that is involved in normal inflammatory and immune responses associated with the symptoms of PsA. The safety and efficacy of TREMFYA in PsA have b...
Source: Johnson and Johnson - July 14, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Stop TB Partnership and Johnson & Johnson, with support from USAID and The Global Fund, Announce Price Reduction for SIRTURO ® (bedaquiline) for Treatment of Drug-Resistant Tuberculosis in Low- and Middle-Income Countries
GENEVA, SWITZERLAND, 6 JULY 2020 – The Stop TB Partnership and Johnson & Johnson – with support from the Global Fund to Fight AIDS, TB and Malaria, and the U.S. Agency for International Development (USAID) – today announced joint efforts to help enable low- and middle-income countries to rapidly scale up use of SIRTURO® (bedaquiline) 100mg tablets in support of new, recently-released World Health Organization (WHO) treatment guidelines. Effective immediately, Johnson & Johnson will make bedaquiline available to Stop TB Partnership’s Global Drug Facility (GDF) at a price of USD$340 per si...
Source: Johnson and Johnson - July 6, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Announces European Commission Approval for Janssen ’s Preventive Ebola Vaccine
Discussions with the U.S. Food and Drug Administration (FDA) have taken place to define the required data set for filing US licensure. About Janssen’s Ebola Vaccine Regimen The Janssen preventive Ebola vaccine regimen, Ad26.ZEBOV and MVA-BN-Filo, utilizes a non-replicating viral vector strategy in which viruses – in this case adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) – are genetically modified so that they cannot replicate in human cells. In addition, these vectors carry the genetic code of several Ebola virus proteins in order to trigger an immune response.Janssen’s vac...
Source: Johnson and Johnson - July 1, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
New Brunswick, NJ (June 30, 2020) - Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Thursday, July 16th to review second-quarter results. Joseph J. Wolk, Executive Vice President, Chief Financial Officer and Christopher DelOrefice, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s executive team.Investors and other interested parties can access the webcast/conference call in the following ways:The webcast and presentation material are accessible at...
Source: Johnson and Johnson - June 30, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
SPRING HOUSE, PENNSYLVANIA, June 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today its decision to discontinue the Phase 3 LOTUS study of STELARA® (ustekinumab) in Systemic Lupus Erythematosus (SLE) due to lack of efficacy in SLE.The decision is based on data from a pre-planned interim efficacy analysis. Interim safety findings were consistent with the known safety profile of STELARA, and no new safety signals were identified. Investigators, study participants and health authorities have been informed of the decision. The company intends to thoroughly analyze the totality of...
Source: Johnson and Johnson - June 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Announces Winners of 2020 Women in STEM2D Scholars Award
(New Brunswick, N.J. – June 18) – Johnson & Johnson today announced the six winners of the third annual Johnson & Johnson Women in STEM2D (WiSTEM2D) Scholars Award. Each recipient, representing each of the STEM2D disciplines: Science, Technology, Engineering, Math, Manufacturing and Design, will receive a grant of $150,000 and three years of mentorship. Launched in June 2017, the Johnson & Johnson WiSTEM2D Scholars Award seeks to fuel development of future female STEM2D leaders and feed the STEM2D talent pipeline by awarding and sponsoring women at critical points in their careers. The goal is to su...
Source: Johnson and Johnson - June 18, 2020 Category: Pharmaceuticals Source Type: news

Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, NJ, June 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumab[i] in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare and potentially fatal disease.[1],[2] The data demonstrated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a higher hematologic complete response rate (CR), (53 percent vs. 18 percent [P
Source: Johnson and Johnson - June 15, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson to Participate in Bank of America Virtual Conference
New Brunswick, NJ (June 10, 2020) -- Johnson & Johnson (NYSE: JNJ) will participate in the Bank of America Virtual Conference on Tuesday, June 23rd. Joseph J. Wolk, Executive Vice President and Chief Financial Officer will represent the Company in a session scheduled at 2:30 p.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.A webcast replay will be available approximately two hours after the live webcast. (Source: Johnson and Johnson)
Source: Johnson and Johnson - June 10, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate; Phase 1/2a Clinical Trial to Begin in Second Half of July
NEW BRUNSWICK, N.J., June 10, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Initially scheduled to begin in September, the trial is now expected to commence in the second half of July. Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson, said, “Based on the strength of the preclinical data we have seen so far and inter...
Source: Johnson and Johnson - June 10, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news